Provider: View Press Release
Type: Link
Title: GSK to present updates on its industry-leading infectious disease portfolio at IDWeek 2022 | GSK
Description: GSK will share updates on its industry-leading infectious disease pipeline and portfolio with 33 abstracts accepted for IDWeek 2022.
Provider: View Press Release
Type: Link
Title: US FDA approves BOOSTRIX for immunisation during pregnancy for the prevention of whooping cough in newborn infants | GSK
Description: The US FDA has approved Boostrix for immunisation during the third trimester of pregnancy to help prevent pertussis (whooping cough).
Provider: View Press Release
Type: Link
Title: GSK announces positive headline results from PERLA, the phase II trial of Jemperli (dostarlimab) plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer | GSK
Description: The PERLA phase II trial is the largest global head-to-head trial of programmed death receptor-1 (PD-1) inhibitors in this population.
Provider: View Press Release
Type: Link
Title: Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as successor | GSK
Description: The Board has selected Ms Julie Brown, currently Chief Operating and Financial Officer, Burberry Group plc, as successor to Iain Mackay.
Provider: View Press Release
Type: Link
Title: Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA phase III trial in recurrent ovarian cancer | GSK
Description: The US FDA will convene a meeting of the Oncologic Drugs Advisory Committee (ODAC) to discuss overall survival data from the Nova trial
Provider: View Press Release
Type: Link
Title: GSK and Spero Therapeutics announce exclusive licence agreement for tebipenem HBr, a late-stage antibiotic that may treat complicated urinary tract infections | GSK
Description: GSK has entered into an exclusive license agreement with Spero Therapeutics for tebipenem pivoxil HBr.